calendar
305 catalysts · 4,301 phase readout · 2,247 8k filing · 282 earnings · 172 phase 2 completion · 93 drug shortage · 73 phase 1 completion
next 91 dayslessmore
MonWedFri
305 catalysts · 4,301 phase readout · 2,247 8k filing · 282 earnings · 172 phase 2 completion · 93 drug shortage · 73 phase 1 completion
Sponsor: EXTROVIS. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: QUAGEN. Form: SYRUP. Route: ORAL
Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: GLENMARK SPECLT. Form: CREAM. Route: TOPICAL
Sponsor: MARKSANS PHARMA. Form: CAPSULE, DELAYED RELEASE. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL
Anticipated earnings call for NOVARTIS AG ($NVS).
Sponsor: ACCORD HLTHCARE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: CAPSULE. Route: ORAL
Anticipated earnings call for ACME UNITED CORP ($ACU).
Anticipated earnings call for Sanofi ($SNY).
Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome (Preleukemia)
Therapy area: Oncology. Indication: Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma
Therapy area: Gastrointestinal. Indication: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)
Therapy area: Cardiovascular, Gastrointestinal. Indication: Endothelial Dysfunction, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)
Anticipated earnings call for INCYTE CORP ($INCY).
Anticipated earnings call for ECOLAB INC. ($ECL).
Anticipated earnings call for Orion Group Holdings Inc ($ORN).
Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Prostate Cancer, Prostate Cancer
Anticipated earnings call for AbbVie Inc. ($ABBV).
Anticipated earnings call for ASTRAZENECA PLC ($AZN).
Anticipated earnings call for GSK plc ($GSK).
Anticipated earnings call for REGENERON PHARMACEUTICALS, INC. ($REGN).
Anticipated earnings call for TEVA PHARMACEUTICAL INDUSTRIES LTD ($TEVA).
Anticipated earnings call for GLAUKOS Corp ($GKOS).
Anticipated earnings call for BIOGEN INC. ($BIIB).
Anticipated earnings call for Bausch & Lomb Corp ($BLCO).
Anticipated earnings call for SBA COMMUNICATIONS CORP ($SBAC).
Anticipated earnings call for AGIOS PHARMACEUTICALS, INC. ($AGIO).
Anticipated earnings call for IONIS PHARMACEUTICALS INC ($IONS).
Anticipated earnings call for Avantor, Inc. ($AVTR).
Anticipated earnings call for MERIT MEDICAL SYSTEMS INC ($MMSI).
Anticipated earnings call for Merck & Co., Inc. ($MRK).
Anticipated earnings call for CARDINAL HEALTH INC ($CAH).
Anticipated earnings call for DEXCOM INC ($DXCM).
Anticipated earnings call for ELI LILLY & Co ($LLY).
Anticipated earnings call for STRYKER CORP ($SYK).
Anticipated earnings call for BRISTOL MYERS SQUIBB CO ($BMY).
Anticipated earnings call for AMGEN INC ($AMGN).
Anticipated earnings call for BIOMARIN PHARMACEUTICAL INC ($BMRN).
Anticipated earnings call for BAXTER INTERNATIONAL INC ($BAX).
Anticipated earnings call for CORCEPT THERAPEUTICS INC ($CORT).